Cookie use on MRCVSonline
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive all cookies.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Ketamine to become Class B drug
Ketamine
New evidence suggests frequent, high doses of ketamine cause chronic toxicity.
Serious harm caused by misuse, latest review warns

Ketamine is to be become a Class B drug after a report recently highlighted growing evidence of serious physical and psychological harm where the drug is heavily and frequently misused.

Minister for crime prevention Norman Baker confirmed the move following a review by the Advisory Council on the Misuse of Drugs (ACMD).

In its first review of the drug since 2004, the council also recommended ketamine be placed in Schedule II of the Misuse of Drugs Regulations 2001.

Ketamine is widely used in veterinary medicine as an anaesthetic and analgesic, as well as some areas of human medicine.

According to the ACMD, 120,000 individuals are estimated to have misused ketamine in 2012 to 2013.

The council's latest report details new evidence of chronic toxicity to the bladder resulting in numerous reports of individuals having to have their bladders removed.

In addition to this, for regular high-dose users the drug is believed to cause a range of psychological and physical problems, as well as significant toxicity to the urinary tract and kidneys.

In a letter to ACMD, Mr Baker said: "I accept your recommendation to reclassify ketamine as a Class B drug. I have taken this decision in light of the evidence of chronic harms associated with ketamine use, including chronic bladder and other urinary tract damage highlighted in the Advisory Council's report."

Mr Baker added that parliamentary proceedings to reclassify the drug will begin shortly. A consultation will be held on the rescheduling of ketamine in order to determine the effect this will have on veterinary and healthcare sectors.

Become a member or log in to add this story to your CPD history

Regional Representatives nominations sought

News Story 1
 Seven new regional representatives are being sought by the British Veterinary Association (BVA) to speak for vets from those regions and to represent their views to BVA Council.

The opportunities are available in in the North-East, Yorkshire & Humber, East Midlands, West Midlands, London, Wales, and Northern Ireland. Representatives from all sectors of the veterinary profession are urged to apply.

BVA president Daniella Dos Santos, said: "Our regional representatives are integral to that mission and to the activities of Council - contributing to effective horizon scanning on matters of veterinary policy and providing an informed steer to BVA’s Policy Committee.” 

Click here for more...
News Shorts
Livestock Antibody Hub receives funding boost

The Pirbright Institute has received US $5.5 million from the Bill and Melinda Gates Foundation to form a Livestock Antibody Hub aimed at supporting animal and human health. The work will bring together researchers from across the UK utilise research outcomes in livestock disease and immunology.

Dr Doug Brown, chief executive of the British Society for Immunology, commented: “The UK is a world leader in veterinary immunology research, and this transformative investment from the Bill & Melinda Gates Foundation will drive the next chapter of innovation in developing new treatments and prevention options against livestock diseases".